Fennec Pharmaceuticals Inc (TSE:FRX) – Investment analysts at Wedbush reduced their FY2018 earnings per share estimates for shares of Fennec Pharmaceuticals in a research note issued on Wednesday, November 14th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings per share of ($0.71) for the year, down from their previous estimate of ($0.70). Wedbush also issued estimates for Fennec Pharmaceuticals’ Q4 2018 earnings at ($0.23) EPS, Q2 2019 earnings at ($0.28) EPS, Q3 2019 earnings at ($0.30) EPS, Q4 2019 earnings at $4.46 EPS, FY2019 earnings at $3.63 EPS, FY2020 earnings at $0.30 EPS, FY2021 earnings at $1.16 EPS and FY2022 earnings at $3.27 EPS.

Separately, Dawson James reiterated a “buy” rating on shares of Fennec Pharmaceuticals in a research report on Wednesday, October 10th.

Shares of Fennec Pharmaceuticals stock opened at C$8.89 on Monday. Fennec Pharmaceuticals has a 12 month low of C$7.90 and a 12 month high of C$18.86.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Featured Article: Return on Investment (ROI) Defined, Explained

Earnings History and Estimates for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.